Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept in Neovascular AMD (PANDA-1)
NCT03577899Phase 3Terminated
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 22
01
Overview
A Phase 3 trial of conbercept in neovascular age-related macular degeneration (NVAMD), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Sep 2018; status: terminated.
02
Drugs
conbercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03577899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577899.